Showing results (41-50 of 96) with videos related to

Sort By:
Pageof 10
Lancet (London, England)|November 9, 2025
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trialLiana K Billings, Stanley Hsia, Harold Bays, et al.
Molecular Metabolism|July 18, 2025
Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weightClaire H Feetham, Minrong Ai, Isabella Culotta, et al.
The Journal of Endocrinology|August 22, 2015
Dual effects of fibroblast growth factor 21 on hepatic energy metabolismRicardo J Samms, Michelle Murphy, Maxine J Fowler, et al.
Plos One|June 8, 2012
Fundamentals of FGF19 & FGF21 action in vitro and in vivoAndrew C Adams, Tamer Coskun, Armando R Irizarry Rovira, et al.
Lancet (London, England)|June 29, 2023
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USAJulio Rosenstock, Juan Frias, Ania M Jastreboff, et al.
Frontiers in Endocrinology|September 18, 2025
Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatideThomas R Pieber, Eva Svehlikova, Shweta Urva, et al.
Plos One|April 4, 2014
A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptorLucy S Jun, Aaron D Showalter, Nosher Ali, et al.
The Lancet. Diabetes & Endocrinology|April 25, 2022
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trialTim Heise, Andrea Mari, J Hans DeVries, et al.
EJNMMI Research|August 7, 2025
Tissue-specific and whole-body insulin sensitivity by integrated imaging and hyperinsulinemic euglycemic clamp: A repeatability study in people with T2DM and overweight/obesityIina Laitinen, Helena Litorp, Folke Sjöberg, et al.
The Journal of Clinical Endocrinology and Metabolism|May 14, 2026
Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 DiabetesMackenzie J Pearson, Jill A Willency, Yanzhu Lin, et al.
Pageof 10